Implementation of Risk-Stratified Tuberculosis Screening in Psoriasis Patients Receiving Biologic Therapy
收藏NIAID Data Ecosystem2026-05-10 收录
官方服务：
资源简介：
Supplementary Tables for Article.
应用场景：
创建时间：
2026-02-26
相关数据集
Supplementary Material for: Switching Biologics in the Treatment of Psoriasis: A Multicenter Experience
Background/Objective: The purpose of our study was to provide evidence on the treatment choices, reasons, and results of switching between biologic agents in treating patients with psoriasis. Methods:
NIAID Data Ecosystem40
Biologic therapy in psoriasis patients with current or previous solid tumor malignancy: A systematic review
Psoriasis is a helper T cell 17-driven chronic inflammatory disease. Although targeted biologics revolutionized management, the utility and safety of biologics in psoriasis patients with current or p
NIAID Data Ecosystem20
Bibliometric analysis and description of research trends in the treatment of psoriasis with biologic agents in the past two decades (2004–2023)
Biologics are essential in treating psoriasis. In recent years, the pathogenesis exploration and development of new target drugs have provided a more complete evidence-based foundation for the biologi
DataCite Commons2024-12-16 更新20
Supplementary Material for: Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients
Background/Aims: This study aimed to investigate the predicting values of depression and anxiety symptoms for clinical response to etanercept treatment in psoriasis patients. Methods: A total of 85 ps
NIAID Data Ecosystem30
Successful experience of secukinumab and ixekizumab in treating erythrodermic psoriasis: A single-center, retrospective study
Erythrodermic psoriasis (EP) is a rare, severe, potentially life-threatening form of psoriasis. Laboratory results may present abnormalities such as leukocytosis, serum albumin loss, and elevated C-re
NIAID Data Ecosystem20
